Vatiquinone
Phase 3Active 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Dec 8, 2022 โ Dec 31, 2027
NCT ID
NCT05515536About Vatiquinone
Vatiquinone is a phase 3 stage product being developed by PTC Therapeutics for Friedreich Ataxia. The current trial status is active. This product is registered under clinical trial identifier NCT05515536. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07159139 | Pre-clinical | Active |
| NCT05515536 | Phase 3 | Active |
| NCT05485987 | Phase 2 | Completed |
| NCT05218655 | Phase 3 | Completed |
| NCT04378075 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Friedreich Ataxia